Reformulated Gout Drug Protects Against Cardiac Events
The U.S. Food & Drug Administration has approved colchicine (Lodoco®) for reducing cardiovascular (CVD) events in patients with atherosclerosis or at high CVD risk. The first anti-inflammatory drug approved for this purpose, Lodoco is taken daily with or without a statin or other lipid-lowering drug.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Heart Advisor
Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
